Static Transwells struggle with hard compounds
Low-permeability and poorly soluble candidates yield weak signals and less reliable data in standard static Caco-2 setups.
Investors
Scalable, flow-enabled Transwell assays for pharma — starting with intestinal permeability.
Updated November 2026
Low-permeability and poorly soluble candidates yield weak signals and less reliable data in standard static Caco-2 setups.
More predictive dynamic systems often need pumps, tubing and specialised workflows discovery teams cannot run routinely.
Pharma needs physiological flow inside the familiar plate workflow — not a replacement of their assay infrastructure.
A working technological principle, early biological signals and first commercial traction — with validation still underway.
Early partners


MACplate + MACnet bring controlled physiological flow into a standard Transwell workflow — without pumps or tubing. Teams keep their inserts, dosing, sampling and read-outs.
Protected magnetic-cilia know-how, spun out of Eindhoven University of Technology.
See FlowGUT — our beachhead assay
Focused for a seed round — with a clear path to venture scale.
Intestinal permeability beachhead
Routine discovery assays
More applications, same plate
Higher throughput next
MACnet actuation (illustrative ~€20k) with recurring MACplate consumables — a tools model discovery labs already understand.
Beachhead where permeability pain is acute.
Paying pharma and CRO partners.
Routine-ready 24-well system.
Broader screening through service labs.
Today
Working principle, first traction, product and biological validation underway.
Seed
Productise 24-well, robust benchmark, 2–3 pharma pilots, 96-well development, manufacturing scale-up.
Series A ready
A product pharma can use routinely — with evidence and a clear scale path.




Origin & partners






Preparing
€3M
seed round
Seeking life sciences investors with expertise in tools, preclinical R&D or drug discovery.
Prefer a conversation? Reach out after requesting the deck.
Laure van der Sanden